RVU.WA

Ryvu Therapeutics S.A. [RVU.WA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

RVU.WA Stock Summary

Top 10 Correlated ETFs

RVU.WA

Top 10 Correlated Stocks

RVU.WA

In the News

RVU.WA Financial details

Company Rating
-
Market Cap
1.26B
Income
-92.17M
Revenue
46.86M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
270
Optionable
No
Shortable
Yes
Earnings
13 Mar 2024
P/E
-17.52
Forward P/E
-
PEG
14.3
P/S
21.52
P/B
4.46
P/C
-
P/FCF
-96.42
Quick Ratio
4.57
Current Ratio
4.62
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-4.01
EPS next Y
-
EPS next Q
-
EPS this Y
-12.04%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
12.31%
Revenue last 5Y
1.94%
Revenue Q/Q
-7.06%
EPS Q/Q
51.9%
-
-
-
-
SMA20
32.36%
SMA50
11.77%
SMA100
-30.42%
Inst Own
-
Inst Trans
-
ROA
-17%
ROE
-23%
ROC
-0.2%
Gross Margin
70%
Oper. Margin
-125%
Profit Margin
-121%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
53.5-72.4
52W High
-55%
52W Low
-38.87%
RSI
64.48
Rel Volume
9.54
Avg Volume
7.6K
Volume
72.44K
Perf Week
14.08%
Perf Month
62%
Perf Quarter
-30.17%
Perf Half Y
-35.2%
-
-
-
-
Beta
0.598
-
-
Volatility
0.97%, 4.19%
Prev Close
-1.67%
Price
32.4
Change
-5.4%

Something similar

Top by Market Cap
VTSAX
MIX.JO
AMZN
0YXG.L
MSF.DE
Top Correlated ETFs
FLES.L
BB3M.L
SMTC.L
TIGR.L
JEST.DE
Top Correlated Stocks
IMB.L
TEN.WA
MTL.L
0HK4.L
BBGI.L
Similar Market Cap
0NLY.L
3686.TW
OUT1V.HE
002775.SZ
0KRR.L

Company Profile

Healthcare Biotechnology
  • Volume Average 7.6K
  • Market Capitalization 1.26B
  • Employee 270
  • CEO Mr. Pawel Tadeusz Przewiezlikowski M.B.A., M.Sc.
  • Headquarters Kraków,PL
  • IPO Date 2011-07-14
  • Website https://www.ryvu.com

Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company's products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia. In addition, its early pipeline candidates include candidates in the area of kinases, cancer metabolism, synthetic lethality, and immuno-oncology. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.